Teva Pharmaceutical Industries (TEVA) to Release Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is expected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, July 30th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.64 per share and revenue of $4.34 billion for the quarter.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter last year, the business posted $0.48 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. On average, analysts expect Teva Pharmaceutical Industries to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.53 on Monday. The firm has a market capitalization of $18.96 billion, a price-to-earnings ratio of -14.38, a PEG ratio of 0.97 and a beta of 0.60. The business’s 50-day moving average price is $16.93 and its 200-day moving average price is $16.74. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares of the company’s stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A hedge fund recently raised its stake in Teva Pharmaceutical Industries stock. AQR Capital Management LLC lifted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 24.6% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,955 shares of the company’s stock after buying an additional 4,732 shares during the period. AQR Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $368,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on TEVA. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a “buy” rating and a $24.00 target price on the stock. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average target price of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.